Expanding access to treatment of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and pediatric acute-onset neuropsychiatric syndrome.

HB 1741 requires most Washington health insurance plans (excluding public employee plans) to cover intravenous immunoglobulin (IVIG) therapy for children diagnosed with PANDAS (pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections) or PANS (pediatric acute-onset neuropsychiatric syndrome). Plans must cover three initial monthly IVIG treatments plus additional courses as medically necessary, but only after two or more less intensive treatments have been tried without success (e.g., ineffective, intolerable, or failing to improve symptoms). A pediatric subspecialist consultation is mandatory, and patients must be reevaluated every three months. The law applies to health plans renewed on or after January 1, 2026.